IRIDEX (NASDAQ:IRIX) Major Shareholder Shih-Yao David Lin Purchases 20,000 Shares of Stock

IRIDEX Corporation (NASDAQ:IRIX) major shareholder Shih-Yao David Lin purchased 20,000 shares of the company’s stock in a transaction that occurred on Thursday, January 8th. The shares were purchased at an average cost of $1.20 per share, with a total value of $24,000.00. Following the completion of the acquisition, the insider owned 971,299 shares in the company, valued at $1,165,558.80. The trade was a 2.10% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

IRIDEX Price Performance

Shares of NASDAQ IRIX opened at $0.88 on Thursday. The stock’s fifty day moving average price is $0.73 and its two-hundred day moving average price is $0.95. IRIDEX Corporation has a one year low of $0.61 and a one year high of $1.65. The firm has a market cap of $15.46 million, a price-to-earnings ratio of -4.40 and a beta of 0.67.

IRIDEX (NASDAQ:IRIX) last posted its quarterly earnings data on Tuesday, August 18th. The medical equipment provider reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.06). The business had revenue of $12.57 million during the quarter, compared to analysts’ expectations of $13.59 million. On average, equities analysts anticipate that IRIDEX Corporation will post -0.12 earnings per share for the current fiscal year.

IRIDEX News Summary

Here are the key news stories impacting IRIDEX this week:

• Positive Sentiment: SEC disclosures show Lin made dozens of purchases totaling substantial share amounts, including transactions of 50,000 shares at $0.99, 40,114 shares at $1.00 and 80,000 shares at $1.00. The repeated buying and growing ownership stake may be interpreted as a sign of confidence in IRIDEX’s long-term prospects. IRIDEX major shareholder buys 50,000 shares
• Positive Sentiment: The filings also include purchases at prices ranging from approximately $0.84 to $1.52, with several individual transactions valued between roughly $20,000 and $58,000. This broad pattern of buying, rather than a single isolated trade, likely attracted speculative interest in the thinly traded stock. IRIDEX major shareholder acquires stock
• Neutral Sentiment: Investors should note that most purchases occurred weeks or months earlier, from March through June and in prior reporting periods; the disclosures are new, but the buying itself is not. The reports therefore provide sentiment support rather than evidence of a new operating development or immediate improvement in revenue and earnings.
• Neutral Sentiment: Trading in IRIX was temporarily halted under a Limit Up-Limit Down (LULD) pause, indicating that the stock’s rapid move exceeded permitted price bands. This highlights significant volatility and the potential for sharp reversals once trading resumes.

Hedge Funds Weigh In On IRIDEX

A number of hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp bought a new position in IRIDEX during the 2nd quarter worth $29,000. Diversify Advisory Services LLC bought a new stake in shares of IRIDEX during the 2nd quarter valued at $30,000. Diversify Wealth Management LLC acquired a new stake in shares of IRIDEX during the 1st quarter worth $35,000. United Capital Financial Advisors LLC acquired a new stake in shares of IRIDEX during the 2nd quarter worth $41,000. Finally, Thompson Davis & CO. Inc. increased its position in shares of IRIDEX by 66.5% in the first quarter. Thompson Davis & CO. Inc. now owns 47,444 shares of the medical equipment provider’s stock worth $48,000 after purchasing an additional 18,944 shares during the period. Institutional investors own 20.10% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 2nd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, IRIDEX currently has a consensus rating of “Hold” and an average target price of $3.00.

IRIDEX Company Profile

IRIDEX Corporation (NASDAQ: IRIX) develops and sells ophthalmic laser systems and related delivery devices used in the treatment of eye diseases. Its products are designed primarily for ophthalmologists treating glaucoma and retinal disorders, including diabetic retinopathy and other conditions affecting the retina.

The company’s portfolio includes laser systems such as the Cyclo G6 glaucoma laser platform and the IQ series of retinal photocoagulation lasers. IRIDEX also offers specialized probes and other delivery devices, including MicroPulse and transscleral cyclophotocoagulation technologies, which are intended to provide targeted treatment while limiting exposure to surrounding tissue.

Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves eye-care professionals through a combination of direct sales and distributor relationships in the United States and international markets.